WO2011058982A1 - 消化器疾患治療剤 - Google Patents
消化器疾患治療剤 Download PDFInfo
- Publication number
- WO2011058982A1 WO2011058982A1 PCT/JP2010/069967 JP2010069967W WO2011058982A1 WO 2011058982 A1 WO2011058982 A1 WO 2011058982A1 JP 2010069967 W JP2010069967 W JP 2010069967W WO 2011058982 A1 WO2011058982 A1 WO 2011058982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ser
- gastrointestinal
- peptide
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Definitions
- the present invention relates to a therapeutic or prophylactic agent for gastrointestinal diseases comprising, as an active ingredient, a peptide whose amino acid sequence is represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof.
- the present invention also relates to (a) a peptide whose amino acid sequence is represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof, and (b) an amino acid sequence of Phe-Gly-Leu-Met-NH 2. Or a pharmaceutically acceptable salt thereof as an active ingredient.
- the digestive tract is an organ responsible for digestion of food and absorption of nutrients, and nutrients necessary for maintaining life are ingested through the mucosal tissue of the intestinal tract.
- the gastrointestinal mucosal tissue contracts due to pathological or surgical disorders, or ulcers occur in the membrane tissue, causing gastrointestinal dysfunction, the permeability of the intestinal mucosa is abnormal. May increase.
- the mucosal tissue of the gastrointestinal tract is atrophied by powerful radiation exposure, intestinal surgery, drugs, and other stimuli that impair cell proliferation. As described above, if the digestive tract is invaded or shrunken, serious digestive tract disorders are caused. Therefore, rapid healing of the digestive tract and recovery of the function of the digestive tract are desired.
- a peptide whose amino acid sequence is represented by Ser-Ser-Ser-Arg (hereinafter referred to as “SSSR”) is a partial peptide of insulin-like growth factor-I, and its amino acid sequence is Phe-Gly-Leu.
- peptide represented by -Met-NH 2 (hereinafter referred to as "FGLM-NH 2”) is a C-terminal tetrapeptide of substance P.
- the present inventors conducted a pharmacological test using small intestinal mucosal tissue cells to promote SSSR to promote cell migration of gastrointestinal mucosal tissue cells, and further digestive diseases such as recovery of gastrointestinal damage. It has been found that it exerts an excellent effect in the treatment of this and has reached the present invention. Furthermore, it has been found that when SSSR and FGLM-NH 2 are used in combination, these drugs act synergistically to significantly promote cell migration of gastrointestinal mucosal tissue cells even when SSSR is at a low concentration.
- the present invention is a therapeutic or prophylactic agent for digestive diseases containing SSSR or a pharmaceutically acceptable salt thereof, and FGLM-NH 2 or a pharmaceutically acceptable salt thereof as an active ingredient, and ( a) a peptide whose amino acid sequence is represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof, and (b) a peptide whose amino acid sequence is represented by Phe-Gly-Leu-Met-NH 2 or a peptide thereof It is a therapeutic or prophylactic agent for digestive system diseases containing a pharmaceutically acceptable salt as an active ingredient.
- pharmaceutically acceptable salts include, for example, hydrochloride, sulfate, phosphate, lactate, acetate, trifluoroacetate, formate, maleate, fumarate, oxalate, Examples include methanesulfonate, paratoluenesulfonate, and the like.
- SSSS is more preferably acetate and trifluoroacetate
- FGLM-NH 2 is more preferably hydrochloride and trifluoroacetate.
- examples of the digestive tract include organs such as the esophagus, stomach, duodenum, small intestine, and large intestine.
- digestive tract diseases include ulcerative or inflammatory digestive tract diseases and abnormal mucosal permeability.
- diseases such as digestive tract diseases, digestive tract excision, radiation exposure or acquired digestive absorption disorders due to radiation-induced gastrointestinal damage or congenital digestive absorption disorders.
- ulcerative digestive organ diseases include not only peptic ulcers but also acute mucosal lesions such as erosion and acute ulcers.
- the therapeutic or preventive agent for digestive tract disease of the present invention is expected to be effective for treating or preventing mucosal pathology and dumping syndrome due to inflammatory diseases such as enteritis, Crohn's disease, ulcerative colitis, Furthermore, healing of surgical invasion can be promoted and gastrointestinal function can be improved.
- the agent for treating or preventing digestive tract diseases of the present invention can be administered orally or parenterally.
- the dosage form include tablets, capsules, granules, powders, injections, and the like, which can be formulated using a widely used technique.
- excipients such as lactose, mannitol, starch, crystalline cellulose, light anhydrous silicic acid, calcium carbonate, calcium hydrogen phosphate, stearic acid, stearin Lubricants such as magnesium acid and talc, binders such as starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, disintegrants such as carboxymethylcellulose, low-substituted hydroxypropylcellulose, calcium citrate, hydroxypropylmethylcellulose, macro It can be prepared using a coating agent such as gall and silicone resin, a stabilizer such as ethyl paraoxybenzoate and benzyl alcohol, and a flavoring agent such as sweetener, acidulant and fragrance as required.
- a coating agent such as gall and silicone resin, a stabilizer such as ethyl paraoxybenzoate and benzyl alcohol, and a flavoring agent such as sweetener, acidulant and fragrance as required.
- isotonic agents such as sodium chloride and concentrated glycerin
- buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monooleate, polyoxy 40 stearate, poly
- a surfactant such as oxyethylene hydrogenated castor oil, a stabilizer such as sodium citrate and sodium edetate, and a preservative such as benzalkonium chloride and paraben can be used as necessary.
- the dosage of the therapeutic agent or prophylactic agent for digestive system diseases of the present invention can be appropriately selected depending on symptoms, age, dosage form and the like.
- SSSR or a pharmaceutically acceptable salt thereof when used as a single agent, it is usually administered in an amount of 0.01 to 5000 mg, preferably 0.01 to 1000 mg per day, in one or several divided doses. can do.
- SSSR or a pharmaceutically acceptable salt thereof and FGLM-NH 2 or a pharmaceutically acceptable salt thereof are used in combination, the SSSR or a pharmaceutically acceptable salt thereof is usually 0.0001 to 500 mg per day.
- 0.001 to 100 mg can be administered in a single dose or divided into several doses, and FGLM-NH 2 or a pharmaceutically acceptable salt thereof is usually 0.001 to 5000 mg per day, preferably 0.01-1000 mg can be administered once or divided into several times.
- SSSR salts have the effect of promoting cell migration of gastrointestinal mucosal tissue cells. Therefore, SSSR or pharmaceutically acceptable salts thereof are due to ulcerative or inflammatory digestive tract diseases, digestive tract diseases resulting from abnormal mucosal permeability, gastrointestinal resection, radiation exposure or drug-based gastrointestinal damage. It is expected to exert an effect as a therapeutic agent or preventive agent for various digestive tract diseases such as acquired digestive absorption disorder or acquired digestive absorption disorder.
- Tablet Formula 1 1000mg SSSR trifluoroacetate 100mg Lactose 700mg Corn starch 100mg Carboxymethylcellulose calcium 50mg Hydroxypropylcellulose 43mg Magnesium stearate 7mg
- a coating agent for example, a coating agent such as hydroxypropylmethylcellulose, macrogol, silicone resin, hypromellose phthalate
- a desired tablet can be obtained by appropriately changing the amount of the additive.
- a coating agent for example, a coating agent such as hydroxypropylmethylcellulose, macrogol, silicone resin, hypromellose phthalate
- a desired tablet can be obtained by appropriately changing the amount of the additive.
- a coating agent for example, a coating agent such as hydroxypropylmethylcellulose, macrogol, silicone resin, hypromellose phthalate
- a desired tablet can be obtained by appropriately changing the amount of the additive.
- a desired capsule can be obtained by appropriately changing the mixing ratio of the drug and lactose and filling the capsule.
- the raw material for the capsule gelatin, hydroxypropylmethylcellulose, or the like can be used.
- a desired capsule can be obtained by appropriately changing the mixing ratio of the drug and lactose and filling the capsule.
- the raw material for the capsule gelatin, hydroxypropylmethylcellulose, or the like can be used.
- Formula 3 150mg SSSR acetate 0.05mg FGLM-NH 2 hydrochloride 10mg Lactose 139.95mg
- a desired capsule can be obtained by appropriately changing the mixing ratio of the drug and lactose and filling the capsule.
- the raw material for the capsule gelatin, hydroxypropylmethylcellulose, or the like can be used.
- the present invention relates to ulcerative or inflammatory gastrointestinal diseases, gastrointestinal diseases resulting from abnormalities in mucosal permeability, gastrointestinal resection, radiation exposure, or acquired digestive absorption disorders due to radiation-induced gastrointestinal damage or congenital digestion.
- a therapeutic or prophylactic agent for digestive diseases such as absorption disorders.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
ヒト結腸癌由来細胞株であるCaco-2細胞を用いて、以下の方法で細胞移動への影響を検討した。
タイプIVコラーゲンでコートした24穴プレートに1穴当たり1×105個のCaco-2細胞を播き、全面を覆うまで10%FBSを含むDMEM培地で培養した。カミソリの刃を用いて細胞層に切れ目を入れ綿棒で無細胞領域を作成し、1%FBSを含むDMEM培地で洗浄後、各被験化合物を含む同培地で37℃・5%CO2の条件下で18時間培養した。被験化合物添加前及び添加18時間後に写真撮影し、一定区画での添加18時間後の細胞伸展面積を比較することにより、Caco-2細胞の細胞移動への影響を検討した。また、被験化合物を含まない培地で同様に培養したものをコントロールとした。
SSSR単剤を用いた場合の結果を表1に示し、また、SSSRとFGLM-NH2を併用した場合の結果を表2に示す。表中のCaco-2細胞移動は、コントロールの細胞移動を基準(100%)として算出した各8例の平均値および標準誤差である。なお、**は、コントロールに対しp<0.001で統計学的に有意であることを示す。
表1より、30μMのSSSRトリフルオロ酢酸塩は、Caco-2細胞移動を促進することが明らかである。
本発明の消化器疾患の治療剤または予防剤の一般的な製剤例を以下に示す。
処方1 1000mg中
SSSRトリフルオロ酢酸塩 100mg
乳糖 700mg
トウモロコシデンプン 100mg
カルボキシメチルセルロースカルシウム 50mg
ヒドロキシプロピルセルロース 43mg
ステアリン酸マグネシウム 7mg
上記処方の錠剤に、コーティング剤(例えば、ヒドロキシプロピルメチルセルロース、マクロゴール、シリコン樹脂、ヒプロメロースフタル酸エステル等のコーティング剤)を用いてコーティングを施し、目的とするコーティング錠を得る。また、添加物の量を適宜変更することにより、所望の錠剤を得ることができる。
SSSRトリフルオロ酢酸塩 1mg
FGLM-NH2トリフルオロ酢酸塩 200mg
乳糖 600mg
トウモロコシデンプン 100mg
カルボキシメチルセルロースカルシウム 50mg
ヒドロキシプロピルセルロース 43mg
ステアリン酸マグネシウム 6mg
上記処方の錠剤に、コーティング剤(例えば、ヒドロキシプロピルメチルセルロース、マクロゴール、シリコン樹脂、ヒプロメロースフタル酸エステル等のコーティング剤)を用いてコーティングを施し、目的とするコーティング錠を得る。また、添加物の量を適宜変更することにより、所望の錠剤を得ることができる。
SSSR酢酸塩 0.1mg
FGLM-NH2塩酸塩 10mg
乳糖 650.9mg
トウモロコシデンプン 200mg
カルボキシメチルセルロースカルシウム 80mg
ヒドロキシプロピルセルロース 50mg
ステアリン酸マグネシウム 9mg
上記処方の錠剤に、コーティング剤(例えば、ヒドロキシプロピルメチルセルロース、マクロゴール、シリコン樹脂、ヒプロメロースフタル酸エステル等のコーティング剤)を用いてコーティングを施し、目的とするコーティング錠を得る。また、添加物の量を適宜変更することにより、所望の錠剤を得ることができる。
処方1 150mg中
SSSRトリフルオロ酢酸塩 100mg
乳糖 50mg
薬物と乳糖の混合比を適宜変更してカプセルに充填することにより、所望のカプセル剤を得ることができる。カプセルの原料には、ゼラチンやヒドロキシプロピルメチルセルロース等を用いることができる。
SSSRトリフルオロ酢酸塩 0.1mg
FGLM-NH2トリフルオロ酢酸塩 10mg
乳糖 139.9mg
薬物と乳糖の混合比を適宜変更してカプセルに充填することにより、所望のカプセル剤を得ることができる。カプセルの原料には、ゼラチンやヒドロキシプロピルメチルセルロース等を用いることができる。
SSSR酢酸塩 0.05mg
FGLM-NH2塩酸塩 10mg
乳糖 139.95mg
薬物と乳糖の混合比を適宜変更してカプセルに充填することにより、所望のカプセル剤を得ることができる。カプセルの原料には、ゼラチンやヒドロキシプロピルメチルセルロース等を用いることができる。
Claims (12)
- アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類を有効成分として含有する消化器疾患の治療剤または予防剤。
- 下記成分(a)および(b)の組合せを有効成分として含有する消化器疾患の治療剤または予防剤:
(a)アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類、
(b)アミノ酸配列がPhe-Gly-Leu-Met-NH2で表されるペプチドまたはその医薬として許容される塩類。 - 消化器疾患が潰瘍性若しくは炎症性の消化器疾患、粘膜透過性の異常に起因する消化器疾患、消化管切除、放射線被曝若しくは薬剤に基づく消化管の損傷による後天的消化吸収障害または先天的消化吸収障害である請求項1または請求項2記載の消化器疾患の治療剤または予防剤。
- 剤型が経口剤である請求項1または請求項2記載の消化器疾患の治療剤または予防剤。
- アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類の治療上有効な量を、治療を必要とする患者に投与することからなる消化器疾患の治療または予防方法。
- 下記成分(a)および(b)の治療上有効な量を、組合せで、治療を必要とする患者に投与することからなる消化器疾患の治療または予防方法:
(a)アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類、
(b)アミノ酸配列がPhe-Gly-Leu-Met-NH2で表されるペプチドまたはその医薬として許容される塩類。 - 消化器疾患が潰瘍性若しくは炎症性の消化器疾患、粘膜透過性の異常に起因する消化器疾患、消化管切除、放射線被曝若しくは薬剤に基づく消化管の損傷による後天的消化吸収障害または先天的消化吸収障害である請求項5または請求項6記載の消化器疾患の治療または予防方法。
- 投与が経口投与である請求項5または請求項6記載の消化器疾患の治療または予防方法。
- 消化器疾患を治療または予防するための、アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類。
- 消化器疾患を治療または予防するための、下記成分(a)および(b)の組合せ:
(a)アミノ酸配列がSer-Ser-Ser-Argで表されるペプチドまたはその医薬として許容される塩類、
(b)アミノ酸配列がPhe-Gly-Leu-Met-NH2で表されるペプチドまたはその医薬として許容される塩類。 - 消化器疾患が潰瘍性若しくは炎症性の消化器疾患、粘膜透過性の異常に起因する消化器疾患、消化管切除、放射線被曝若しくは薬剤に基づく消化管の損傷による後天的消化吸収障害または先天的消化吸収障害である、請求項9記載のペプチドまたはその塩類、若しくは請求項10記載のペプチドまたはその塩類の組合せ。
- 経口治療剤または予防剤の製造のための、請求項9記載のペプチドまたはその塩類、若しくは請求項10記載のペプチドまたはその塩類の組合せ。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012123992/15A RU2577302C2 (ru) | 2009-11-11 | 2010-11-10 | Терапевтическое средство против желудочно-кишечного заболевания |
CA2779417A CA2779417A1 (en) | 2009-11-11 | 2010-11-10 | Therapeutic agent for gastrointestinal disease |
US13/505,627 US20120225817A1 (en) | 2009-11-11 | 2010-11-10 | Therapeutic agent for gastrointestinal disease |
KR1020127012120A KR20120127390A (ko) | 2009-11-11 | 2010-11-10 | 소화기 질환 치료제 |
EP10829941.3A EP2500029A4 (en) | 2009-11-11 | 2010-11-10 | THERAPEUTIC AGENT FOR DISEASES OF THE STOMACH DARM TRAKTS |
CN201080051086.0A CN102612373B (zh) | 2009-11-11 | 2010-11-10 | 消化器官疾病治疗剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009257569 | 2009-11-11 | ||
JP2009-257569 | 2009-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011058982A1 true WO2011058982A1 (ja) | 2011-05-19 |
Family
ID=43991640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/069967 WO2011058982A1 (ja) | 2009-11-11 | 2010-11-10 | 消化器疾患治療剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120225817A1 (ja) |
EP (1) | EP2500029A4 (ja) |
JP (1) | JP5707101B2 (ja) |
KR (1) | KR20120127390A (ja) |
CN (1) | CN102612373B (ja) |
CA (1) | CA2779417A1 (ja) |
RU (1) | RU2577302C2 (ja) |
WO (1) | WO2011058982A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101869783B1 (ko) * | 2016-08-17 | 2018-06-22 | (주)진셀팜 | 미백 활성이 우수한 펩타이드, 및 이의 용도 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62501212A (ja) * | 1984-12-11 | 1987-05-14 | エニ−ヘル エセ ピ ア | サブスタンスp及びそのフラグメントの誘導体 |
JPH04502922A (ja) * | 1989-08-16 | 1992-05-28 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 治療用ペプチド |
JPH05504142A (ja) * | 1990-02-13 | 1993-07-01 | グロペップ プロプライエタリー リミテッド | 腸疾患用薬剤 |
JPH1017489A (ja) * | 1996-06-26 | 1998-01-20 | Teruo Nishida | 眼科用医薬組成物 |
JPH10505076A (ja) * | 1994-09-08 | 1998-05-19 | ノバルティス アクチェンゲゼルシャフト | 炎症反応の抑制のためのインシュリン様成長因子iおよびiiの使用 |
JP2002226395A (ja) * | 2000-08-10 | 2002-08-14 | Teruo Nishida | 皮膚創傷治癒促進剤 |
JP2003231695A (ja) | 2001-12-03 | 2003-08-19 | Teruo Nishida | 新規ペプチドおよびその医薬用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56164156A (en) * | 1980-09-29 | 1981-12-17 | Zen Ito | Preparation of polypeptide |
US5679771A (en) * | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
TWI305778B (en) * | 2001-12-03 | 2009-02-01 | Nishida Teruo | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use |
RU2355415C2 (ru) * | 2007-07-04 | 2009-05-20 | Федеральное Государственное Унитарное Предприятие " Государственный научно-исследовательский институт особо чистых биопрепаратов " Федерального медикобиологического агентства | Способ лечения повреждений слизистой оболочки желудочно-кишечного тракта |
-
2010
- 2010-11-10 KR KR1020127012120A patent/KR20120127390A/ko not_active Application Discontinuation
- 2010-11-10 EP EP10829941.3A patent/EP2500029A4/en not_active Withdrawn
- 2010-11-10 CN CN201080051086.0A patent/CN102612373B/zh not_active Expired - Fee Related
- 2010-11-10 JP JP2010251370A patent/JP5707101B2/ja not_active Expired - Fee Related
- 2010-11-10 US US13/505,627 patent/US20120225817A1/en not_active Abandoned
- 2010-11-10 WO PCT/JP2010/069967 patent/WO2011058982A1/ja active Application Filing
- 2010-11-10 RU RU2012123992/15A patent/RU2577302C2/ru not_active IP Right Cessation
- 2010-11-10 CA CA2779417A patent/CA2779417A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62501212A (ja) * | 1984-12-11 | 1987-05-14 | エニ−ヘル エセ ピ ア | サブスタンスp及びそのフラグメントの誘導体 |
JPH04502922A (ja) * | 1989-08-16 | 1992-05-28 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 治療用ペプチド |
JPH05504142A (ja) * | 1990-02-13 | 1993-07-01 | グロペップ プロプライエタリー リミテッド | 腸疾患用薬剤 |
JPH10505076A (ja) * | 1994-09-08 | 1998-05-19 | ノバルティス アクチェンゲゼルシャフト | 炎症反応の抑制のためのインシュリン様成長因子iおよびiiの使用 |
JPH1017489A (ja) * | 1996-06-26 | 1998-01-20 | Teruo Nishida | 眼科用医薬組成物 |
JP2002226395A (ja) * | 2000-08-10 | 2002-08-14 | Teruo Nishida | 皮膚創傷治癒促進剤 |
JP2003231695A (ja) | 2001-12-03 | 2003-08-19 | Teruo Nishida | 新規ペプチドおよびその医薬用途 |
Non-Patent Citations (2)
Title |
---|
CHIKAMOTO, N. ET AL.: "Efficacy of Substance P and Insulin-like Growth Factor-1 Peptides for Preventing Postsurgical Superficial Punctate Keratopathy in Diabetic Patients", JPN J OPHTHALMOL, vol. 53, no. 5, 2009, pages 464 - 469, XP019745157 * |
NAOYUKI YAMADA: "Promotion of Corneal Epithelial Wound Healing with a Tetrapeptide (SSSR) Derived from Insulin-like Growth Factor-1", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 112, no. 11, 10 November 2008 (2008-11-10), pages 984 - 993, XP008157410 * |
Also Published As
Publication number | Publication date |
---|---|
RU2577302C2 (ru) | 2016-03-10 |
KR20120127390A (ko) | 2012-11-21 |
JP5707101B2 (ja) | 2015-04-22 |
JP2011121939A (ja) | 2011-06-23 |
EP2500029A4 (en) | 2013-04-24 |
CN102612373A (zh) | 2012-07-25 |
US20120225817A1 (en) | 2012-09-06 |
CA2779417A1 (en) | 2011-05-19 |
EP2500029A1 (en) | 2012-09-19 |
CN102612373B (zh) | 2016-03-02 |
RU2012123992A (ru) | 2013-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018040989A1 (zh) | 依达拉奉与(+)-2-莰醇的舌下用药物组合物 | |
CN110420211A (zh) | 治疗炎症、自身免疫性疾病和疼痛的方法 | |
KR20080046673A (ko) | 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제 | |
ES2384333T3 (es) | Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles | |
WO2009003356A1 (fr) | Composition pharmaceutique pour diminuer l'aire d'un infarctus du myocarde et application de celle-ci | |
WO2017028777A1 (zh) | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 | |
CN113880915A (zh) | 用于修复黏膜损伤或皮肤创伤的多肽及其应用 | |
US20230321039A1 (en) | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof | |
JP2012111773A (ja) | 経口吸収改善用医薬組成物 | |
PL201388B1 (pl) | Preparaty farmaceutyczne w postaci stałej lub ciekłej zawierające pochodną benzamidu jako substancję czynną | |
EP4054537A1 (en) | Oral formulation of x842 | |
JP5707101B2 (ja) | 消化器疾患治療剤 | |
WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
KR102111094B1 (ko) | 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물 | |
CN114432425B (zh) | 一种多肽在预防和治疗胃部疾病的药物中的应用 | |
JP2024501839A (ja) | 腸管洗浄用の経口固形製剤 | |
CN110652510B (zh) | 中乌宁在制备防治肾纤维化药物中的应用 | |
WO2013115740A1 (en) | Synergisctic combination comprising a meglitinide derivative and lipoic acid | |
KR20210141203A (ko) | 에르도스테인 유도체 및 이를 함유하는 약학 조성물 | |
JP2009084207A (ja) | 医薬組成物 | |
KR20050090374A (ko) | 위식도 역류 치료에서의 테나토프라졸의 용도 | |
JP2007145731A (ja) | 止瀉効果を有する内服用製剤 | |
WO2020003107A1 (en) | Low dose oral pharmaceutical composition of pirfenidone or salt thereof | |
US8273721B2 (en) | Combination treatment for bladder cancer | |
KR20230132397A (ko) | 니클로사마이드 또는 이의 약학적으로 허용 가능한염을 포함하는 항 바이러스용 또는 항암용 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080051086.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10829941 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2779417 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20127012120 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010829941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010829941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13505627 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012123992 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: JP |